Literature DB >> 16930782

Characterization of the humoral immune response in dogs after vaccination against the Lyme borreliosis agent A study with five commercial vaccines using two different vaccination schedules.

Katharina H Töpfer1, Reinhard K Straubinger.   

Abstract

Using five commercially available vaccines, groups of dogs were vaccinated against Lyme borreliosis and followed for 13 months. A modified vaccination schedule was included in the study in an attempt to induce higher and therefore longer-lasting protective antibody levels during the first year of immunization. Following vaccination antibodies were monitored using ELISA and Western blotting. Serum samples were examined either with antigen preparations derived from either Borrelia burgdorferi s. s., B. garinii or B. afzelii lysates or separately with recombinant OspA derived from the three species. Regardless of the vaccine used the third vaccination induced significantly higher antibody levels. Further analyses of the sera with homologue and heterologue detection systems showed in vitro only a minor cross-reactivity of vaccinal antibodies towards antigens derived from heterologous Borrelia species in vitro and consequently only minimal cross-protection can be expected.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16930782     DOI: 10.1016/j.vaccine.2006.07.031

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

Review 1.  Lyme borreliosis.

Authors:  Allen C Steere; Franc Strle; Gary P Wormser; Linden T Hu; John A Branda; Joppe W R Hovius; Xin Li; Paul S Mead
Journal:  Nat Rev Dis Primers       Date:  2016-12-15       Impact factor: 52.329

2.  Humoral immune response in dogs naturally infected with Borrelia burgdorferi sensu lato and in dogs after immunization with a Borrelia vaccine.

Authors:  Michael W Leschnik; Georges Kirtz; Gelas Khanakah; Georg Duscher; Ernst Leidinger; Johann G Thalhammer; Anja Joachim; Gerold Stanek
Journal:  Clin Vaccine Immunol       Date:  2010-03-10

3.  Antibodies to Borrelia burgdorferi OspA, OspC, OspF, and C6 antigens as markers for early and late infection in dogs.

Authors:  Bettina Wagner; Heather Freer; Alicia Rollins; David Garcia-Tapia; Hollis N Erb; Christopher Earnhart; Richard Marconi; Patrick Meeus
Journal:  Clin Vaccine Immunol       Date:  2012-02-15

4.  A scoping review of Lyme disease research relevant to public health.

Authors:  J D Greig; I Young; S Harding; M Mascarenhas; L A Waddell
Journal:  Can Commun Dis Rep       Date:  2018-10-04

5.  Borrelia burgdorferi sensu lato species in Europe induce diverse immune responses against C6 peptides in infected mice.

Authors:  Inke Krupka; Jens Knauer; Leif Lorentzen; Thomas P O'Connor; Jill Saucier; Reinhard K Straubinger
Journal:  Clin Vaccine Immunol       Date:  2009-09-02

6.  Human and Veterinary Vaccines for Lyme Disease.

Authors:  Nathaniel S O'Bier; Amanda L Hatke; Andrew C Camire; Richard T Marconi
Journal:  Curr Issues Mol Biol       Date:  2020-12-08       Impact factor: 2.081

Review 7.  The immunopathology of canine vector-borne diseases.

Authors:  Michael J Day
Journal:  Parasit Vectors       Date:  2011-04-13       Impact factor: 3.876

8.  Evaluation of the preventive capacities of a topically applied azithromycin formulation against Lyme borreliosis in a murine model.

Authors:  Jens Knauer; Inke Krupka; Christiane Fueldner; Joerg Lehmann; Reinhard K Straubinger
Journal:  J Antimicrob Chemother       Date:  2011-09-15       Impact factor: 5.790

9.  Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA.

Authors:  Andrew K Eschner; Kristen Mugnai
Journal:  Parasit Vectors       Date:  2015-02-10       Impact factor: 3.876

10.  Borrelia persica Infection in Immunocompetent Mice--A New Tool to Study the Infection Kinetics In Vivo.

Authors:  Sandra Schwarzer; Evelyn Overzier; Walter Hermanns; Gad Baneth; Reinhard K Straubinger
Journal:  PLoS Negl Trop Dis       Date:  2016-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.